Evidence map›Paper›PMID 42150789›Full record

SynthesisJournal of clinical pathology2026

Risk stratification in locally invasive pancreatic serous cystic neoplasms: systematic review and two cases.

Cong Tan, Xinyi Chen, Shu-Juan Ni, Meng Zhang, Xu Cai, Wenhua Jiang, Weiqi Sheng, Dan Huang

Abstract readSystematic ReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cong TanDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0001-6912-4579
Xinyi ChenDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shu-Juan NiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-8030-0294
Meng ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xu CaiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenhua JiangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dan HuangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China danhuang@shca.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCurrent diagnostic criteria for pancreatic serous cystadenocarcinoma (SCC) create a grey zone for tumours that are locally invasive but not yet metastatic. We sought to resolve this ambiguity by defining the clinicopathological features and searching for the malignant potential of this aggressive subset of serous neoplasms.

methodsA combined cohort of 25 patients was compiled from a systematic literature review and augmented with two institutional cases.

resultsInfiltrative growth was a near-universal finding (23/25), often in tumours with a prominent solid architecture. This growth pattern was reflected by frequent local invasion into adjacent organs (40%). The malignant potential of these neoplasms was confirmed by the development of metachronous distant metastases in 28% of patients (median time: 40.5 months) despite their absence at presentation. Our institutional cases highlight the diagnostic value of Ki-67 immunohistochemistry, revealing markedly elevated proliferation indices (5% and 10% in hotspots) that starkly contrast with those of conventional serous cystadenomas (<2%).

conclusionLocal invasion in serous neoplasms, especially when combined with a solid architecture and high Ki-67 index, defines a high-risk subset highly suspicious for serous cystadenocarcinoma. This interpretation must be balanced against the generally indolent behaviour of most serous neoplasms, and such cases warrant closer clinical surveillance.

Indexed as

Cystadenocarcinoma, SerousPancreatic NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryKi-67 AntigenMaleMiddle AgedNeoplasm InvasivenessRisk AssessmentBiomarkers, TumorKi-67 AntigenKi-67 AntigenPancreatic NeoplasmsPathology, Surgical

Identifiers

PMID42150789
PMCPMC13479205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.